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doi:10.1016/j.jmii.2010.06.001Background: Infections due to carbapenem-resistant Enterobacteriaceae have been the
emerging problem worldwide. This primary object of this study was to understand the risk
factors and clinical outcomes of carbapenem-nonsusceptible Escherichia coli (CNSEc) bacter-
emia.
Methods: We conducted a matched caseecontrol study in a 3,715-bed tertiary care medical
center in northern Taiwan. The controls were selected among patients with carbapenem-
susceptible E coli and were matched with CNSEc for bacteremia.
Results: Fifty-one patients were included in this study (17 cases and 34 controls). Bivariate
analysis showed that prior exposure to carbapenems (p< 0.001), stay in intensive care units
(pZ 0.016), placement of central venous catheters (pZ 0.001), chronic liver diseases
(p< 0.001), uremia with regular dialysis (pZ 0.004), and mechanical ventilation (pZ 0.004)
were associated with CNSEc bacteremia. Multivariate analysis revealed that prior exposure
to carbapenems [odds ratio (OR), 29.17; 95% confidence interval (CI), 1.76e484.70;
pZ 0.019], uremia with regular dialysis (OR, 98.58; 95% CI, 4.02e999; pZ 0.005) and chronic
liver diseases (OR, 27.86; 95% CI, 2.31e335.83; pZ 0.009) were independent risk factors for
CNSEc bacteremia. Compared with carbapenem-susceptible E coli group, CNSEc group had
a longer hospital stay (68.4 days vs. 35.8 days; pZ 0.04) and a higher disease severity, asfectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital, 5 Fu-Shin Street,
com (M.-H. Lee).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
126 H.-J. Chang et al.indicated by a Pittsburgh bacteremia score greater than or equal to 4 (5.6% vs. 2.5%;
pZ 0.015). Patients with CNSEc bacteremia had a higher overall in-hospital mortality rate
(94.12% vs. 50.00%; pZ 0.002), but there was no difference in the 28-day mortality between
these two groups.
Conclusions: CNSEc bacteremia would lead to a poor outcome among patients with prior expo-
sure to carbapenems, chronic liver disease, and uremia with regular dialysis.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Carbapenem antibiotics have been the cornerstone of
treatment for serious infections because of multidrug-
resistant gram-negative pathogens. Carbapenem resistance
used to be uncommon in the past few years but has now been
increasing among the Enterobacteriaceae worldwide,1e4
particularly Klebsiella pneumoniae.5 Infections caused by
carbapenem-resistant K pneumoniae have been reported,
and clinical outcomes and risk factors of carbapenem-
resistant K pneumoniae infections have been well
studied.6e8
The emergence and spread of carbapenem-nonsusceptible
(intermediately resistant or resistant) Escherichia coli
(CNSEc) is also becoming a clinical challenge for physicians.4,9
The mechanism of producing carbapenem resistance in E coli
is mostly attributable to an outer-membrane porin deficiency
combinedwithCMY-2-/CMY-4-relatedAmpCenzymes,CTX-M-
type/SHV-12 extended-spectrum-b-lactamases (ESBL) or IMP-
8-type metallo-b-lactamase.1,10e13 Recently, OXA-48-like
carbapenemases and outer-membrane protein loss were also
reported.14
To date, risk factors for CNSEc acquisition have not been
well described. There were only limited observation and
clinical experience in the treatment of infections caused by
CNSEc, especially bacteremia. Bloodstream infections
caused by organisms with highly antibiotic resistance are
associated with increased rates of treatment failure and
mortality.15 Hence, we conducted a matched caseecontrol
study to identify the potential risk factors for the devel-
opment of CNSEc bacteremia and to investigate the
outcomes of patients with CNSEc bacteremia.
Materials and methods
Study design and patients
This study was conducted at the Chang Gung Memorial
Hospital-Taoyuan, a 3,715-bed tertiary care medical center.
In this retrospective study, the blood culture records at the
microbiology laboratory databases were reviewed to iden-
tify all the bacteremia caused by CNSEc between January
2006 and December 2008. All identified patients were
enrolled, and their medical charts were reviewed. The
clinical information was collected, such as demographics,
dates of hospital admission and discharge, and dates of blood
cultures. For patients with more than one episode of infec-
tion because of E coli, only data relevant to the first episode
were collected and analyzed. The exposure to various riskfactors was taken into consideration in the analysis only if it
had occurred before the development of the infection.
Variables analyzed as risk factors are summarized in Table 1,
including comorbid illness, recent hospitalization (14 days)
and surgery, intensive care unit (ICU) stay, mechanical
ventilation, tracheotomy, placement of central venous
catheters (CVCs), Foley catheter insertion, implantation of
prosthesis, cardiovascular and endovascular catheteriza-
tion, endoscopic procedures, the Pittsburgh bacteremia
score for disease severity,16 and previous exposure to various
antibiotic agents. Exposure to a specific antimicrobial agent
was considered significant in our analysis only if (1) that
exposure had occurred only during the hospitalization in
which infection developed and (2) the antibiotic had been
administered for at least 3 consecutive days before the
development of the infection.
Selection of controls
For each patient with CNSEc bacteremia, we selected two
matched control patients from the pool of patients with
carbapenem-susceptible E coli (CSEc) bacteremia. We used
a stepwise matching technique to identify the appropriate
control patient matched to a case for gender, age 5
years, year of hospital admission, and length of hospital
stay up to the isolation of E coli 6 days.
Microbiological analysis
Blood cultures were processed in the clinical microbiology
laboratory, using the automated blood culture system
(BACTEC 9240 system; Becton Dickinson Diagnostic Instru-
ment Systems, Sparks, MD, USA). The isolated organisms
that grew on culture were identified according to routine
bacteriological procedures. Antibiotic susceptibility testing
was determined by the disk diffusion method in accordance
with the criteria of the Clinical and Laboratory Standards
Institute (CLSI).17 The antibiotic disks (BD Microbiology
Systems, Cockeysville, MD, USA) for Enterobacteriaceae
included amoxicillineclavulanic acid, piperacillin, piper-
acillinetazobactam, cefazolin, cefuroxime, ceftriaxone,
ceftazidime, aztreonam, gentamicin, amikacin, cipro-
floxacin and ertapenem. Quality control was performed
testing E coli ATCC 25922, Pseudomonas aeruginosa ATCC
27853, K pneumoniae ATCC 700603, and E coli ATCC 35218.
Interpretations of disk diffusion results were made using
CLSI document M100-S19.18 Carbapenem nonsusceptibility
was initially screened with ertapenem disk diffusion testing
on the basis of the CLSI document M100-S19 and was
Table 1 Clinical characteristics of 51 patients with bacteremia caused by Escherichia coli with and without the carbapenem-
nonsusceptible phenotype
Characteristics Carbapenem-nonsusceptible
group (nZ 17)
Carbapenem-susceptible
group (nZ 34)
p
Demographic
Sex, male 10 (58.82) 20 (58.82) 1.000
Age 67.2 14.7 (40e94) 67.4 15.6 (36e94) 0.974
Length of hospital stay (d) 68.4 56.4 (7e161) 35.8 34.5 (4e141) 0.040*
Duration before bacteremia (d) 36.7 39.6 (1e131) 21.9 28.5 (0e125) 0.133
Comorbidities
Heart diseasesa 3 (17.65) 2 (5.88) 0.318
Malignancies (solid tumor) 6 (35.29) 12 (35.29) 1.000
COPD 2 (11.76) 3 (8.82) 1.000
Uremia with regular dialysis 6 (35.29) 1 (2.94) 0.004*
Diabetes mellitus 7 (41.18) 10 (29.41) 0.401
Chronic liver diseasesb 13 (76.47) 6 (17.65) <0.001*
Hematological diseases 2 (11.76) 2 (5.88) 0.530
Immunosuppressant usec 3 (17.65) 8 (23.53) 0.731
Previous transplantations 3 (17.65) 0 0.033*
Readmission within 14 dd 7 (41.18) 6 (17.65) 0.093
Intensive care unit stay 11 (64.71) 10 (29.41) 0.016*
Mechanical ventilation support 11 (64.71) 8 (23.53) 0.004*
Pittsburgh bacteremia score 5.6 4.4 (1e14) 2.5 2.6 (0e11) 0.015*
Invasive procedure or devices
Central venous catheters 12 (70.59) 8 (23.53) 0.001*
Foley catheter insertion 6 (35.29) 5 (14.71) 0.147
Surgery 6 (35.29) 9 (26.47) 0.515
Prosthesis placement 6 (35.29) 6 (17.65) 0.181
Colostomy/gastrotomy 0 3 (8.82) 0.542
Tracheostomy 3 (17.65) 2 (5.88) 0.318
Prior antibiotic exposure
Penicillin/ampicillin/amoxicillin 1 (5.88) 2 (5.88) 1.000
b-Lactam/b-lactam-lactamase inhibitor 1 (5.88) 2 (5.88) 1.000
Anti-pseudomonal penicillins 1 (5.88) 1 (2.94) 1.000
1st- and 2nd-generation cephalosporins 0 2 (5.88) 0.547
3rd-Generation cephalosporins 8 (47.06) 9 (26.47) 0.142
4th-Generation cephalosporins 4 (23.53) 3 (8.82) 0.203
Aminoglycosides 2 (11.76) 7 (20.59) 0.699
Fluoroquinolones 7 (41.18) 6 (17.65) 0.093
Metronidazole 3 (17.65) 1 (2.94) 0.102
Clindamycin 0 1 (2.94) 1.000
Carbapenems 9 (52.94) 1 (2.94) <0.001*
Outcome
Mortality, 14 d 8 (47.06) 13 (38.24) 0.546
Days from culture to death, 14 d 3.8 3.8 (0e11) 5.8 4.5 (1e12) 0.289
Mortality, 28 d 12 (70.59) 16 (47.06) 0.111
Days from culture to death, 28 d 9.8 9.6 (0e24) 9.4 8.6 (1e25) 0.895
Mortality, overall 16 (94.12) 17 (50.00) 0.002*
Days from culture to death, overall 34.5 48.1 (0e160) 10.6 9.7 (1e30) 0.069
Microbial eradication 7 (41.18) 22 (64.71) 0.110
Favorable (cure or improvement) 1 (5.88) 17 (50.00) 0.002*
Unfavorable (stationary or deterioration) 16 (94.12) 17 (50.00)
a Heart diseases included congestive heart failure and valvular heart diseases.
b Chronic liver diseases included liver cirrhosis and chronic hepatitis.
c Immunosuppressant use included administration of steroids or immunosuppressant agents for non-hemaoncologic diseases.
d Readmitted from health care centers or hospitals within 14 d.
* Statistically significant, p< 0.05.
Data are presented as mean  standard deviation (range) or n(%).
COPDZ chronic obstructive pulmonary diseases.
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Figure 1. Survival analysis of patients with bacteremia
caused by Escherichia coli with and without the carbapenem-
nonsusceptible phenotype (pZ 0.3994).
128 H.-J. Chang et al.confirmed by imipenem disk diffusion, according to estab-
lished methods and breakpoints,18 and by the Etest
methods with imipenem and ertapenem, according to the
manufacturer’s instructions (AB Biodisk, Solna, Sweden).
Definition of outcomes
The primary outcome measure was in-hospital mortality.
Secondary outcome was the outcome of the infection, and
this was assessed as either favorable (cure or improvement)
or unfavorable (stationary or deterioration).
Statistical methods
Descriptive statistics, including the number of observations,
mean and standard deviation, were used to summarize the
continuous variables. Frequency and proportion were used
to summarize the categorical variables. For the continuous
variables, Student t test or Wilcoxon test was considered
for the test statistics, depending on the validity of the
normality assumption. Chi-square test or Fisher’s exact test
was used to test the categorical variables. Multivariate
analysis was performed using logistic regression to identify
factors that independently and significantly affected the
outcome. Variables with a p value less than 0.05 in bivariate
analyses were considered for inclusion in a multivariate
model. The Statistical Analysis System (SAS) (Version 9.1;
SAS Institute Inc., Cary, NC, USA) was used as the
programming software for performing the analysis.
Results
From January 2006 to December 2008, 51 patients were
included in this study (17 cases with CNSEc and 34 controls
with CSEc). The patients’ characteristics are summarized in
Table 1. Matching was achieved for all 17 cases with CNSEc
bacteremia. Matching variables included gender, age, and
length of hospital stay up to the isolation of E coli.
Patients with CNSEc bacteremia were mostly health care
associated, either by nosocomial acquisition or by being
transferred from nursing home or regional hospitals. Among
the 17 patients with CNSEc bacteremia, 13 came from
different wards, and no outbreaks were detected during the
study period. Cross infection in hospital wards seemed less
likely. As for the rest of the four patients, two were
admitted in the medical intensive care unit, but the dates of
their positive blood cultures for CNSEc were 9 months apart.
Another two patients were admitted to the same gastroin-
testinal ward, but the culture dates were 4 months apart.
Therefore, the 17 CNSEc isolates were unlikely from the
limited clones. Besides, an earlier study using eight of our
studied patients investigated the development of carbape-
nem resistance in E coli. Eight pairs of E coli isolates with
various carbapenem susceptibilities from eight patients
were prospectively collected to study. Identical pulsed-field
gel electrophoresis patterns were found in carbapenem-
susceptible and -resistant isolates, but different pulsed-
field gel electrophoresis patterns occurred among the
patients.1
Compared with the CSEc group, the CNSEc group had
more patients with uremia on regular dialysis (35.29% vs.2.94%; pZ 0.004), with chronic liver diseases (76.47% vs.
17.65%; p< 0.001), and receiving transplantation (including
liver and kidney transplantation, 17.65% vs. 0%; pZ 0.033).
Of 17 patients with CNSEc bacteremia, seven (41.18%) had
recent access to health care facilities, such as residence in
a nursing home, or recent hospital admission. However,
there was no statistically significant difference of this
parameter in comparison with that in the CSEc group
(41.18% vs. 17.65%; pZ 0.093).
For the patients with CNSEc bacteremia, 12 (70.59%) had
the placement of CVCs and 11 (64.71%) had been admitted
to an ICU with mechanical ventilator support at the onset of
CNSEc bacteremia. Both conditions were seen to a lesser
extent in patients with CSEc bacteremia [8 (23.53%) and
10 (29.41%), respectively]. Previous antibiotic exposure,
particularly to carbapenems, was more frequently seen
in patients with CNSEc bacteremia (52.94% vs. 2.94%;
p< 0.001). As shown in Table 1, CNSEc bacteremia group
had a longer hospital stay (68.4 days vs. 35.8 days;
pZ 0.04) and a disease severity, as indicated by a Pitts-
burgh bacteremia score greater than or equal to 4 (5.6% vs.
2.5%; pZ 0.015). The clinical course after the onset of
bacteremia was different between these two groups.
Patients with CNSEc bacteremia had a higher overall in-
hospital mortality rate (94.12% vs. 50.00%; pZ 0.002) and
more unfavorable outcome than those with CSEc bacter-
emia, but there was no statistical difference in the 28-day
mortality between these two groups (Fig. 1).
Using the statistically significant parameters (p< 0.05)
shown in Table 1, bivariate analysis showed that prior
exposure to carbapenems (p< 0.001), ICU stay (pZ 0.016),
CVC placement (pZ 0.001), chronic liver diseases
(p< 0.001), uremia with regular dialysis (pZ 0.004), and
mechanical ventilation (pZ 0.004) were associated with
CNSEc bacteremia. Multivariate analysis showed that prior
exposure to carbapenems [odds ratio (OR), 29.17; 95%
confidence interval (CI), 1.76e484.70; pZ 0.019]; uremia
with regular dialysis (OR, 98.58; 95% CI, 4.02e999;
pZ 0.005); and chronic liver diseases (OR, 27.86; 95% CI,
2.31e335.83; pZ 0.009) were independent risk factors for
the development of CNSEc bacteremia (Table 2).
Table 2 Multivariable analysis of risk factors for carbapenem-nonsusceptible Escherichia coli bacteremia
Factors Odds ratio 95% Confidence interval p
Uremia with regular dialysis 98.58 4.02e999.99 0.005*
Chronic liver diseases 27.86 2.31e335.83 0.009*
Previous use of Carbapenems 29.17 1.76e484.70 0.019*
Only risk factors in Table 1 with p value less than 0.05 were considered for inclusion in a multivariable analysis.
A multivariable regression model was constructed by using a stepwise selection procedure.
* Statistically significant (p< 0.05).
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Emergence of imipenem resistance after long-term imipe-
nememeropenem therapy for a case with recurrent uro-
sepsis because of ESBL-producing E coli has been reported.4
The occurrence of an outer-membrane porin deficiency and
the expression of a plasmid-mediated class C b-lactamase1,13
or carbapenem-hydrolyzing enzymes1,4,19 were reported to
be responsible for carbapenem resistance in E coli.
Risk factors for the development of bacteremia or non-
bacteremic infections caused by carbapenem-resistant E
coli (CREc) or CNSEc have been rarely well described in the
English-language literature. One earlier study by Jeon et
al20 surveyed the risk factors for the acquisition of CREc
among hospitalized patients. A total of 46 patients with
nosocomially acquired CREc isolates were studied. Previous
use of carbapenem and metronidazole, the presence of
biliary drainage catheter, and prior hospital stay were
associated with CREc acquisition.20 The causal association
between metronidazole exposure and acquisition of CREc
was not actually identified by conditional logistic regression
analyses, but most (25 of 46, 54.3%) of the patients were
indeed exposed to metronidazole. Similar to the findings of
Jeon et al,20 our study revealed that prior use of carbape-
nem was an independent risk factor for the emergence of
CNSEc infections but metronidazole was not. That is
because only three patients with CNSEc bacteremia had
biliary drainage and metronidazole exposure.
Multivariate analysis in our study revealed that uremia
with regular dialysis and chronic liver diseases were also
independent risk factors. The greater disease severity,
placement of CVCs, and higher incidence of invasive
procedures might contribute to the acquisition of blood-
stream infections. Vascular deviceserelated bloodstream
infections may be the major transmission route of CNSEc
bacteremia. Patients with such risk factors may also have
repeated hospitalization and longer hospital stay.21
The overall in-hospital mortality in the case group was
almost two times higher than that of the matched controls
(94.12% vs. 50.00%), but there was no statistical difference in
the 28-day mortality between these two groups. It could be
difficult toassess theattributablemortality in this studywhen
both groups had such a high overall mortality. Limited patient
numbers may be another factor for this difficulty. Greater
disease severity andpoor patient conditionmay contribute to
the poor outcome, not the infection itself. Notably, 17.6% (6
of 34)of thematched controls hadbacteremiacausedbyESBL
strains, which had been reported to have high mortality
rate.22However,whether the infectionofmultidrug-resistant
gram-negative bacilli is associated with increasing mortality
is still controversial.23,24Our study has limitations. First, the sample size of
patients included in this study is relatively small, although
this is a common problem in studies assessing risk factors of
infections because of multidrug-resistant pathogens.25
Second, molecular epidemiology investigations using PCR
for resistance genes or sequencing of PCR products were
not performed in our study. Thus, details on the kind of
carbapenemase are not available. Identifying the specific
carbapenemase of the bacterial strains in our study will be
necessary because the minimal inhibitory concentrations
vary with the type of carbapenemase and may have influ-
ences on treatment results.7 Our study afforded the
preliminary data for risk factors of the acquisition of CNSEc
infections and the outcome of patients with such
infections.
In summary, CNSEc bacteremia led to a worse outcome
than CSEc bacteremia. To our knowledge, our study is the
first to show the association between CNSEc bacteremia
and the underlying comorbid illness (i.e. chronic liver
diseases and uremia with regular dialysis).Acknowledgment
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